The current standard of care in the neoadjuvant setting for resectable high-risk HER2 + breast cancer is to combine chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab, for a synergistic anti-tumour effect [1, 2]. The gene discussed is ERBB2; the disease is neoplasm.